Telaprevir/boceprevir era: From bench to bed and back

doi:10.3748/wjg.v18.i43.6183

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 43

This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7758)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series.

Item

Count

PDF

376

HTML

4216

Figures (1-2)

249

Sum=4841

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1417

Download

1500

Sum=2917

Nov 21, 2012 (publication date) through Nov 29, 2024

Times Cited of This Article

Times Cited (25)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Field Of Vision

World J Gastroenterol. Nov 21, 2012; 18(43): 6183-6188
Published online Nov 21, 2012. doi: 10.3748/wjg.v18.i43.6183

Full Size Figure Download Figure

Figure 1 The outcome of the five landmark trials for telaprevir-based triple therapy in hepatitis C virus genotype 1 patients. Sustained virologic response rates are compared between groups. PROVE 1, PROVE 2 and ADVANCE trials were conducted in treatment-naïve patients. PROVE 3 and REALIZE trials were conducted in treatment-experienced patients. T: Telaprevir; P: Peg-IFN; R: Ribavirin; The numbers (8, 12, 24 or 48): Week of treatment; SVR: Sustained virologic response.

Citation: Pan Q, Peppelenbosch MP, Janssen HL, Knegt RJ. Telaprevir/boceprevir era: From bench to bed and back. World J Gastroenterol 2012; 18(43): 6183-6188
URL: https://www.wjgnet.com/1007-9327/full/v18/i43/6183.htm
DOI: https://dx.doi.org/10.3748/wjg.v18.i43.6183